We found that miR181b-5p levels were significantly reduced in LC patients who received four cycles of pembrolizumab, which could potentially restore E-cadherin levels and reduce cancer cell migration and metastasis, showing a positive outcome for pembrolizumab treatment. This evidence concerns the gene CDH1 and laryngotracheoesophageal cleft.